Drug updated on 4/18/2024
| Dosage Form | Injection (subcutaneous; 13.2 mg/0.6 mL) |
| Drug Class | Leukocyte growth factors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Summary
- Eflapegrastim (Rolvedon) is used to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
- A study focused on the effectiveness and safety of long-acting granulocyte colony-stimulating factors (LA-G-CSFs), including eflapegrastim, was reviewed.
- The study indicates that a 13.2 mg dosage of eflapegrastim significantly outperforms other LA-G-CSFs in reducing the incidence of febrile neutropenia and severe neutropenia without introducing significant severe adverse events, thereby enhancing treatment efficacy without compromising safety.
- At this higher dosage level, eflapegrastim does not result in a significant increase in severe adverse events when compared to other dosages or LA-G-CSFs, suggesting it offers a favorable safety profile for patient management during chemotherapy.
- The benefits of this drug are specifically targeted towards adult patients with breast cancer undergoing myelosuppressive chemotherapy; however, the study did not provide detailed information about its effects on different population subgroups such as varying cancer types or pediatric populations.
- When compared to other LA-G-CSF regimens like lipegfilgrastim and possibly others unspecified, eflapegrastim at 13.2 mg is one of the most effective options for managing chemotherapy-induced neutropenia among breast cancer patients due to its high efficacy rate coupled with minimal safety concerns.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rolvedon (eflapegrastim-xnst) prescribing information. | 2022 | Spectrum Pharmaceuticals Inc., Irvine, CA |